Long Anterior ZonulesNCT07549711
Morphological-Gene-Clinical Phenotype Correlation Study of the Long Anterior Zonule
An observational study of Long Anterior Zonules, run by Fuzhou Eye Hospital at 1 site in China.
Trial summary
Long anterior zonules (LAZ) is an anatomical anomaly of the anterior segment in which zonular fibers extend abnormally forward onto the anterior lens capsule. It is potentially associated with glaucoma, late-onset retinal degeneration, and increased risks during cataract surgery. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Long Anterior Zonules
- What is being tested?
- Long anterior zonules and LAZ Pedigree
- How many people
- 600 participants
- Where
- 1 siteChina
- Study dates
- 10 Jan 2025to 31 Dec 2028
- How long will I take part?
- 1 Month
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: LAZ (Long anterior zonules) is characterized by the abnormal anterior extension of the ciliary zonule fibers, resulting in a significant reduction in the diameter of the central zonule-free zone of the lens.
Who may be able to join
- Control Group Routine cataract patient, no signs of LAZ, intraocular pressure ≤21 mmHg, and no history of glaucoma, pigment dispersion syndrome, or other eye diseases that clearly affect the anterior segment structure.
- LAZ Group Patients with cataracts combined with LAZ were independently evaluated by at least two senior ophthalmologists under slit-lamp examination or a 3D visualization system, and were required to meet the predefined diagnostic criteria for LAZ.
- LAZ Pedigree Cohort First-degree and above relatives of the LAZ proband, aged ≥18 years, regardless of the presence or absence of LAZ or related ocular disease phenotypes.
Who cannot join
- Secondary glaucoma with a clear etiology (such as inflammatory, traumatic, or neovascular glaucoma, etc.)
- History of previous intraocular surgery (e.g., cataract, glaucoma, or vitreoretinal surgery), with refractive surgery history documented but analyzed with caution
- Presence of ocular conditions affecting anterior segment imaging quality, such as corneal leukoma or severe cataract
- Individuals with severe systemic diseases (e.g., poorly controlled diabetes, connective tissue diseases) or mental disorders that hinder cooperation during examinations
- Pregnant or lactating women.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A Morphological, Genetic, and Clinical Phenotype Association Study of the Long Anterior Zonule (LAZ) Based on Multimodal Imaging and Genetic Testing
Long anterior zonules (LAZ) is an anatomical anomaly of the anterior segment in which zonular fibers extend abnormally forward onto the anterior lens capsule. It is potentially associated with glaucoma, late-onset retinal degeneration, and increased risks during cataract surgery. This study introduces a 3D visualization system to enhance the detection rate of LAZ. By integrating multiple imaging modalities, it systematically assesses the morphological characteristics of LAZ, aiming to provide an evidence-based foundation for subsequent efforts to establish diagnostic consensus, optimize preoperative assessments for glaucoma and cataract surgery. By elucidating the genetic mechanisms and genotype-phenotype correlations of LAZ, this research can provide theoretical support for the early identification of high-risk populations, genetic consultation, and personalized treatment.
- Conditions
- Long Anterior Zonules
- Being tested
- Control, Long anterior zonules, LAZ Pedigree
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ControlGenetic
Routine cataract patient, no signs of LAZ, intraocular pressure ≤21 mmHg, and no history of glaucoma, pigment dispersion syndrome, or other eye diseases that clearly affect the anterior segment structure.
Long anterior zonulesGenetic
Patients with cataracts combined with LAZ were independently evaluated by at least two senior ophthalmologists under slit-lamp examination or a 3D visualization system, and were required to meet the predefined diagnostic criteria for LAZ.
LAZ PedigreeGenetic
First-degree and above relatives of the LAZ proband, aged ≥18 years, regardless of the presence or absence of LAZ or related ocular disease phenotypes.
| Study group | Role | What they receive |
|---|---|---|
| Control Group | Not described Receives: Genetic: Control | |
| LAZ Group | Not described Receives: Genetic: Long anterior zonules | |
| LAZ Pedigree Cohort | Not described Receives: Genetic: LAZ Pedigree |
What is being measured
The primary outcome is the main question the study is designed to answer.
Axial length
Axial length, anterior chamber depth, lens thickness, corneal curvature, corneal diameter
Measured: 1 day pre-op
Anterior chamber depth
Measured: 1 day pre-op
Lens thickness
Measured: 1 day pre-op
Corneal curvature
Measured: 1 day pre-op
Corneal diameter (WTW)
Measured: 1 day pre-op
Imaging of LAZ morphology and distribution
The images and videos about slit lamp and 3D visualization system.
Measured: 1 day pre-op
Gene sequencing
Identification of pathogenic genes
Measured: through study completion, an average of 1 year
Secondary outcomes (13)
Uncorrected Visual Acuity (UCVA)
Measured: 1 day pre-op; 1 day post-op; 7 days post-op; 30 days post-op
Corrected Distance Visual Acuity (CDVA)
Measured: 1 day pre-op; 1 day post-op; 7 days post-op; 30 days post-op
Spherical equivalent (SE)
Measured: 1 day pre-op; 1 day post-op; 7 days post-op; 30 days post-op
Intraocular pressure
Measured: 1 day pre-op; 1 day post-op; 7 days post-op; 30 days post-op
Intraoperative complications
Intraoperative capsular complications occur
Measured: Intraoperative
Age
Measured: 1 day pre-op
Sex
Measured: 1 day pre-op
Diagnosis
Diagnosis of accompanying ocular and systemic conditions, such as glaucoma, macular degeneration, hypertension, diabetes, etc.
Measured: 1 day pre-op
Anterior chamber volume (ACV)
Measured: 1 day pre-op
Anterior chamber area (ACA)
Measured: 1 day pre-op
Angle opening distance (AOD)
Measured: 1 day pre-op
Trabecular iris angle (TIA)
Measured: 1 day pre-op
Images of the ciliary body structure
Images of the ciliary body captured by UBM
Measured: 1 day pre-op
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Apr 2026
- Study start10 Jan 2025
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Long Anterior ZonulesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 600 participants (estimated)
- Target duration
- 1 Month
Sponsor and investigators
- Lead sponsor
- Fuzhou Eye Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07549711
- Sponsor's protocol ID
- FZYKYY-KY-2025-005
- Status last verified
- Apr 2026
- First submitted
- 9 Apr 2026
- Last updated
- 24 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Morphological, Genetic, and Clinical Phenotype Association Study of the Long Anterior Zonule (LAZ) Based on Multimodal Imaging and Genetic Testing
- ClinicalTrials.gov ID
- NCT07549711
- Acronym / sponsor ID
- FZYKYY-KY-2025-005
- Conditions
- Long Anterior Zonules
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 600 participants (estimated)
- Lead sponsor
- Fuzhou Eye HospitalUniversity, hospital or other
- Study start
- 10 Jan 2025 (actual)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 24 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Long anterior zonules (LAZ) is an anatomical anomaly of the anterior segment in which zonular fibers extend abnormally forward onto the anterior lens capsule. It is potentially associated with glaucoma, late-onset retinal degeneration, and increased risks during cataract surgery. This study introduces a 3D visualization system to enhance the detection rate of LAZ. By integrating multiple imaging modalities, it systematically assesses the morphological characteristics of LAZ, aiming to provide an evidence-based foundation for subsequent efforts to establish diagnostic consensus, optimize preoperative assessments for glaucoma and cataract surgery. By elucidating the genetic mechanisms and genotype-phenotype correlations of LAZ, this research can provide theoretical support for the early identification of high-risk populations, genetic consultation, and personalized treatment.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Month
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Control Group | – | Genetic: Control |
| LAZ Group | – | Genetic: Long anterior zonules |
| LAZ Pedigree Cohort | – | Genetic: LAZ Pedigree |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- LAZ (Long anterior zonules) is characterized by the abnormal anterior extension of the ciliary zonule fibers, resulting in a significant reduction in the diameter of the central zonule-free zone of the lens.
Key inclusion criteria (3 listed)
- Control Group Routine cataract patient, no signs of LAZ, intraocular pressure ≤21 mmHg, and no history of glaucoma, pigment dispersion syndrome, or other eye diseases that clearly affect the anterior segment structure.
- LAZ Group Patients with cataracts combined with LAZ were independently evaluated by at least two senior ophthalmologists under slit-lamp examination or a 3D visualization system, and were required to meet the predefined diagnostic criteria for LAZ.
- LAZ Pedigree Cohort First-degree and above relatives of the LAZ proband, aged ≥18 years, regardless of the presence or absence of LAZ or related ocular disease phenotypes.
Key exclusion criteria (5 listed)
- Secondary glaucoma with a clear etiology (such as inflammatory, traumatic, or neovascular glaucoma, etc.)
- History of previous intraocular surgery (e.g., cataract, glaucoma, or vitreoretinal surgery), with refractive surgery history documented but analyzed with caution
- Presence of ocular conditions affecting anterior segment imaging quality, such as corneal leukoma or severe cataract
- Individuals with severe systemic diseases (e.g., poorly controlled diabetes, connective tissue diseases) or mental disorders that hinder cooperation during examinations
- Pregnant or lactating women.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ControlRoutine cataract patient, no signs of LAZ, intraocular pressure ≤21 mmHg, and no history of glaucoma, pigment dispersion syndrome, or other eye diseases that clearly affect the anterior segment structure. | Genetic | Control Group |
| Long anterior zonulesPatients with cataracts combined with LAZ were independently evaluated by at least two senior ophthalmologists under slit-lamp examination or a 3D visualization system, and were required to meet the predefined diagnostic criteria for LAZ. | Genetic | LAZ Group |
| LAZ PedigreeFirst-degree and above relatives of the LAZ proband, aged ≥18 years, regardless of the presence or absence of LAZ or related ocular disease phenotypes. | Genetic | LAZ Pedigree Cohort |
Primary outcome
Axial length
Time frame: 1 day pre-op
Axial length, anterior chamber depth, lens thickness, corneal curvature, corneal diameter
Anterior chamber depth
Time frame: 1 day pre-op
Lens thickness
Time frame: 1 day pre-op
Corneal curvature
Time frame: 1 day pre-op
Corneal diameter (WTW)
Time frame: 1 day pre-op
Imaging of LAZ morphology and distribution
Time frame: 1 day pre-op
The images and videos about slit lamp and 3D visualization system.
Gene sequencing
Time frame: through study completion, an average of 1 year
Identification of pathogenic genes
13 secondary outcomes
Uncorrected Visual Acuity (UCVA)
Time frame: 1 day pre-op; 1 day post-op; 7 days post-op; 30 days post-op
Corrected Distance Visual Acuity (CDVA)
Time frame: 1 day pre-op; 1 day post-op; 7 days post-op; 30 days post-op
Spherical equivalent (SE)
Time frame: 1 day pre-op; 1 day post-op; 7 days post-op; 30 days post-op
Intraocular pressure
Time frame: 1 day pre-op; 1 day post-op; 7 days post-op; 30 days post-op
Intraoperative complications
Time frame: Intraoperative
Age
Time frame: 1 day pre-op
Sex
Time frame: 1 day pre-op
Diagnosis
Time frame: 1 day pre-op
Anterior chamber volume (ACV)
Time frame: 1 day pre-op
Anterior chamber area (ACA)
Time frame: 1 day pre-op
Angle opening distance (AOD)
Time frame: 1 day pre-op
Trabecular iris angle (TIA)
Time frame: 1 day pre-op
Images of the ciliary body structure
Time frame: 1 day pre-op
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2026.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Long Anterior Zonules, run by Fuzhou Eye Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 24 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Axial length (time frame: 1 day pre-op). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2026.